Double-Hit Lymphoma: Is Lenalidomide Just Right

In this issue of Blood Advances, Cahill et al 1 report results from an investigator-initiated, single-arm, phase 1/2 study that evaluated the addition of lenalidomide to dose-adjusted (DA) EPOCH-R (DA-EPOCH-R) in patients with double-hit (DHL) or double-expressor (DEL) large B-cell lymphomas.The study demonstrated encouraging response rates and survival outcomes in both cohorts with acceptable tolerability of treatment.